getimage-48-768x274.png
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
September 02, 2021 08:30 ET | Capricor Therapeutics
LOS ANGELES, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and...
getimage-48-768x274.png
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 16:01 ET | Capricor Therapeutics
CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase...
getimage-48-768x274.png
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
August 05, 2021 09:00 ET | Capricor Therapeutics
LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
August 04, 2021 08:00 ET | Capricor Therapeutics
-Preclinical Data Demonstrates Capricor’s Exosome Product as an Antishock Therapeutic if Delivered Early -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS...
getimage-48-768x274.png
Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
July 27, 2021 08:00 ET | Capricor Therapeutics
LOS ANGELES, July 27, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based...
getimage-48-768x274.png
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
June 17, 2021 09:00 ET | Capricor Therapeutics
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based...
getimage-48-768x274.png
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
June 10, 2021 09:15 ET | Capricor Therapeutics
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting
May 18, 2021 08:30 ET | Capricor Therapeutics
-Capricor’s Findings Support Expansion Across Multiple Therapeutic Targets- -Conference will be held virtually: May 18 – May 21- LOS ANGELES, May 18, 2021 (GLOBE NEWSWIRE) -- Capricor...
getimage-48-768x274.png
Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:05 ET | Capricor Therapeutics
---Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- -Data for Phase II INSPIRE Clinical Trial Expected in Third Quarter- -Plan to File IND...
getimage-48-768x274.png
Capricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting
May 12, 2021 09:00 ET | Capricor Therapeutics
--Conference Session: Therapeutic Applications of Extracellular Vesicles: From Diagnostics to Drug Delivery-- LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics...